During the competition, MingCeler Bio showcased its groundbreaking project in the model mouse field—the "New Generation Rapid Animal Model Generation Technology." As a foundational supporting technology platform in the biomedicine and health industry, this project leverages stem cell and tetraploid complementation technology (TurboMice™) as its core, developing an industry-disruptive new generation of mouse modeling technology. It has achieved industrialization and scalability, breaking through the current technical barriers in the mouse model generation industry. The technology aims to shorten modeling cycles, enable rapid customized design, reduce production costs, allow free selection of mouse strains, and enhance the production efficiency of highly complex models.

 

Starting from the ground up and leading the future with innovation, MingCeler Bio has overcome key core technologies in model organism generation, transforming cutting-edge scientific achievements into industrial applications. By integrating industry, academia, and research, the company has established high-value foundational support technologies for new drug development, committed to providing high-value animal models for the biomedicine and health sector. Ultimately, this drives holistic progress in life sciences across production, education, and research in human health. To date, MingCeler Bio has completed an angel funding round exceeding ten million RMB.

 

The innovativeness and breakthrough nature of MingCeler Bio's mouse model generation technology endow it with the following distinctive features:

 

​Rapid Batch Production: The TurboMice™ technology achieves a birth rate of 30%-60% for gene-edited mice generated from embryonic stem cells, the most advanced level in the industry. The modeling cycle is highly predictable, potentially as short as two months, with the first-generation mice being 100% homozygous breeders, eliminating the need for breeding and screening.